H.C. Wainwright Rates Akebia Therapeutics (AKBA) Stock Buy

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 Best Performing Penny Stocks So Far in 2025. On June 4, H.C. Wainwright analysts initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) and gave it a “Buy” rating with a price target of $8.

This decision was based on confidence in the company’s drug, Vafseo (vadadustat), which is used to treat anemia in adults with chronic kidney disease (CKD) who are on dialysis.

H.C. Wainwright Rates Akebia Therapeutics (AKBA) Stock Buy

A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics.

In March 2024, Akebia Therapeutics, Inc. (NASDAQ:AKBA) received FDA approval for Vafseo (vadadustat) for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. Vafseo became available in the US market starting January 2025.

Currently, Vafseo is being rolled out for dialysis patients. However, there is also potential for expansion in the non-dialysis segment. Akebia Therapeutics, Inc. (NASDAQ:AKBA) plans to start a Phase 3 trial for the use of Vafseo (vadadustat) in treating anemia in late-stage CKD patients who are not on dialysis.

H.C. Wainwright analysts expect further growth for Akebia Therapeutics, Inc. (NASDAQ:AKBA) as the drug gains acceptance among dialysis organizations, including large ones.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a fully integrated biopharmaceutical company focused on developing and commercializing therapies for kidney disease.

While we acknowledge the potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AKBA and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.